QQQ   309.16 (-2.90%)
AAPL   122.06 (-2.45%)
MSFT   227.56 (-2.70%)
FB   255.41 (-1.39%)
GOOGL   2,011.41 (-2.57%)
TSLA   653.20 (-4.84%)
AMZN   3,005.00 (-2.89%)
NVDA   512.19 (-4.49%)
BABA   236.27 (+0.79%)
CGC   33.24 (-5.70%)
GE   13.44 (+3.54%)
MU   89.11 (-2.17%)
NIO   41.53 (-4.07%)
AMD   80.86 (-3.89%)
T   28.72 (+1.77%)
F   12.17 (-3.03%)
ACB   10.46 (-5.17%)
DIS   192.26 (-0.87%)
BA   228.56 (+2.43%)
NFLX   520.70 (-4.95%)
PFE   34.39 (+2.63%)
QQQ   309.16 (-2.90%)
AAPL   122.06 (-2.45%)
MSFT   227.56 (-2.70%)
FB   255.41 (-1.39%)
GOOGL   2,011.41 (-2.57%)
TSLA   653.20 (-4.84%)
AMZN   3,005.00 (-2.89%)
NVDA   512.19 (-4.49%)
BABA   236.27 (+0.79%)
CGC   33.24 (-5.70%)
GE   13.44 (+3.54%)
MU   89.11 (-2.17%)
NIO   41.53 (-4.07%)
AMD   80.86 (-3.89%)
T   28.72 (+1.77%)
F   12.17 (-3.03%)
ACB   10.46 (-5.17%)
DIS   192.26 (-0.87%)
BA   228.56 (+2.43%)
NFLX   520.70 (-4.95%)
PFE   34.39 (+2.63%)
QQQ   309.16 (-2.90%)
AAPL   122.06 (-2.45%)
MSFT   227.56 (-2.70%)
FB   255.41 (-1.39%)
GOOGL   2,011.41 (-2.57%)
TSLA   653.20 (-4.84%)
AMZN   3,005.00 (-2.89%)
NVDA   512.19 (-4.49%)
BABA   236.27 (+0.79%)
CGC   33.24 (-5.70%)
GE   13.44 (+3.54%)
MU   89.11 (-2.17%)
NIO   41.53 (-4.07%)
AMD   80.86 (-3.89%)
T   28.72 (+1.77%)
F   12.17 (-3.03%)
ACB   10.46 (-5.17%)
DIS   192.26 (-0.87%)
BA   228.56 (+2.43%)
NFLX   520.70 (-4.95%)
PFE   34.39 (+2.63%)
QQQ   309.16 (-2.90%)
AAPL   122.06 (-2.45%)
MSFT   227.56 (-2.70%)
FB   255.41 (-1.39%)
GOOGL   2,011.41 (-2.57%)
TSLA   653.20 (-4.84%)
AMZN   3,005.00 (-2.89%)
NVDA   512.19 (-4.49%)
BABA   236.27 (+0.79%)
CGC   33.24 (-5.70%)
GE   13.44 (+3.54%)
MU   89.11 (-2.17%)
NIO   41.53 (-4.07%)
AMD   80.86 (-3.89%)
T   28.72 (+1.77%)
F   12.17 (-3.03%)
ACB   10.46 (-5.17%)
DIS   192.26 (-0.87%)
BA   228.56 (+2.43%)
NFLX   520.70 (-4.95%)
PFE   34.39 (+2.63%)
Log in
NASDAQ:EDIT

Editas Medicine Stock Forecast, Price & News

$43.13
-2.56 (-5.60 %)
(As of 03/3/2021 12:00 AM ET)
Add
Compare
Today's Range
$42.00
Now: $43.13
$45.60
50-Day Range
$43.86
MA: $61.08
$76.14
52-Week Range
$14.01
Now: $43.13
$99.95
Volume2.71 million shs
Average Volume2.91 million shs
Market Capitalization$2.91 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.1
Editas Medicine, Inc. operates as a clinical stage genome editing company. The company focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary genome editing platform based on CRISPR technology, which includes CRISPR/Cas9, CRISPR/Cas12a, and engineered forms of both of these CRISPR systems to target genetically addressable diseases and therapeutic areas. It also develops EDIT-101, which is in Phase 1/2 clinical trial for the treatment of Leber Congenital Amaurosis type 10, a genetic form of vision loss that leads to blindness in childhood. In addition, the company develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis pigmentosa 4, a progressive form of retinal degeneration; and EDIT-301 treat sickle cell disease and beta-thalassemia. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; strategic research collaboration Asklepios BioPharmaceutical, Inc. to develop a therapy to treat a neurological disease; and research collaboration with Sandhill Therapeutics, Inc. to develop allogeneic healthy donor derived NK cell medicines for the treatment of solid tumors. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Editas Medicine logo

Headlines

Truist downgrades shares of Editas Medicine
February 28, 2021 |  seekingalpha.com
Editas Medicine EPS misses by $0.12, beats on revenue
February 26, 2021 |  seekingalpha.com
Editas (EDIT) Misses on Q4 Earnings, Beats on Revenues
February 26, 2021 |  finance.yahoo.com
Here's Why Editas Medicine Dropped Today
February 23, 2021 |  finance.yahoo.com
Where Will Editas Medicine Be in 5 Years?
February 17, 2021 |  finance.yahoo.com
Why Editas Medicine Stock Sank Today
February 10, 2021 |  finance.yahoo.com
Where to Invest $1 Million Right Now
January 24, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:EDIT
CUSIPN/A
Phone617-401-9000
Employees208
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$20.53 million
Book Value$5.12 per share

Profitability

Net Income$-133,750,000.00

Miscellaneous

Market Cap$2.91 billion
Next Earnings Date5/6/2021 (Estimated)
OptionableOptionable

MarketRank

Overall MarketRank

1.35 out of 5 stars

Medical Sector

898th out of 1,968 stocks

Biological Products, Except Diagnostic Industry

115th out of 177 stocks

Analyst Opinion: 3.0Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
$43.13
-2.56 (-5.60 %)
(As of 03/3/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive EDIT News and Ratings via Email

Sign-up to receive the latest news and ratings for EDIT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Editas Medicine (NASDAQ:EDIT) Frequently Asked Questions

Is Editas Medicine a buy right now?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Editas Medicine in the last year. There are currently 3 sell ratings, 4 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Editas Medicine stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EDIT, but not buy additional shares or sell existing shares.
View analyst ratings for Editas Medicine
or view top-rated stocks.

What stocks does MarketBeat like better than Editas Medicine?

Wall Street analysts have given Editas Medicine a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Editas Medicine wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Editas Medicine's next earnings date?

Editas Medicine is scheduled to release its next quarterly earnings announcement on Thursday, May 6th 2021.
View our earnings forecast for Editas Medicine
.

How were Editas Medicine's earnings last quarter?

Editas Medicine, Inc. (NASDAQ:EDIT) issued its quarterly earnings results on Thursday, February, 25th. The company reported ($1.00) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.81) by $0.19. The company had revenue of $11.42 million for the quarter, compared to analysts' expectations of $5.64 million. Editas Medicine had a negative trailing twelve-month return on equity of 26.74% and a negative net margin of 99.62%. The business's quarterly revenue was down 7.0% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.74) EPS.
View Editas Medicine's earnings history
.

How has Editas Medicine's stock price been impacted by COVID-19?

Editas Medicine's stock was trading at $20.27 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, EDIT stock has increased by 112.8% and is now trading at $43.13.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for EDIT?

10 brokerages have issued 12 month price targets for Editas Medicine's shares. Their forecasts range from $14.00 to $86.00. On average, they expect Editas Medicine's share price to reach $49.22 in the next year. This suggests a possible upside of 14.1% from the stock's current price.
View analysts' price targets for Editas Medicine
or view top-rated stocks among Wall Street analysts.

Who are Editas Medicine's key executives?

Editas Medicine's management team includes the following people:
  • Ms. Cynthia L. Collins M.B.A., Pres, CEO & Director (Age 63, Pay $1.14M)
  • Dr. Feng Zhang, Co-Founder & Scientific Advisory Board Member
  • Dr. George M. Church, Co-Founder & Scientific Advisory Board Member (Age 67)
  • Dr. J. Keith Joung, Co-Founder & Scientific Advisory Board Member
  • Dr. David R. Liu, Co-Founder & Scientific Advisory Board Member
  • Ms. Michelle Robertson, CFO, Principal Accounting Officer, Treasurer & Assistant Sec. (Age 54)
  • Mr. Harry R. Gill III, Sr. VP of Operations (Age 60)
  • Mr. Mark J. Mullikin, Sr. Director of Fin. & Investor Relations
  • Ms. Charlene Stern, Sr. VP & Chief Legal Officer
  • Ms. Clare Carmichael, Chief HR Officer (Age 61)

Who are some of Editas Medicine's key competitors?

What other stocks do shareholders of Editas Medicine own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Editas Medicine investors own include CRISPR Therapeutics (CRSP), NVIDIA (NVDA), Micron Technology (MU), Intellia Therapeutics (NTLA), Square (SQ), Advanced Micro Devices (AMD), Alibaba Group (BABA), QUALCOMM (QCOM), Cisco Systems (CSCO) and Skyworks Solutions (SWKS).

When did Editas Medicine IPO?

(EDIT) raised $100 million in an IPO on Wednesday, February 3rd 2016. The company issued 5,900,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley and J.P. Morgan acted as the underwriters for the IPO and Cowen and Company and JMP Securities were co-managers.

What is Editas Medicine's stock symbol?

Editas Medicine trades on the NASDAQ under the ticker symbol "EDIT."

Who are Editas Medicine's major shareholders?

Editas Medicine's stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (8.46%), Sumitomo Mitsui Trust Holdings Inc. (7.00%), Nikko Asset Management Americas Inc. (7.00%), Federated Hermes Inc. (2.74%), Credit Suisse AG (1.35%) and Morgan Stanley (1.33%). Company insiders that own Editas Medicine stock include Charles Albright, Cynthia Collins, Jessica Hopfield, Michelle Robertson and Vickesh Myer.
View institutional ownership trends for Editas Medicine
.

Which major investors are selling Editas Medicine stock?

EDIT stock was sold by a variety of institutional investors in the last quarter, including Sumitomo Mitsui Trust Holdings Inc., Nikko Asset Management Americas Inc., Morgan Stanley, BlackRock Inc., Credit Suisse AG, Capital Advisors Inc. OK, Russell Investments Group Ltd., and Hussman Strategic Advisors Inc.. Company insiders that have sold Editas Medicine company stock in the last year include Charles Albright, Cynthia Collins, and Michelle Robertson.
View insider buying and selling activity for Editas Medicine
or view top insider-selling stocks.

Which major investors are buying Editas Medicine stock?

EDIT stock was purchased by a variety of institutional investors in the last quarter, including Norges Bank, Voloridge Investment Management LLC, Great Lakes Advisors LLC, State of Michigan Retirement System, Capital Impact Advisors LLC, Dimensional Fund Advisors LP, Cambridge Investment Research Advisors Inc., and DDD Partners LLC.
View insider buying and selling activity for Editas Medicine
or or view top insider-buying stocks.

How do I buy shares of Editas Medicine?

Shares of EDIT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Editas Medicine's stock price today?

One share of EDIT stock can currently be purchased for approximately $43.13.

How much money does Editas Medicine make?

Editas Medicine has a market capitalization of $2.91 billion and generates $20.53 million in revenue each year. The company earns $-133,750,000.00 in net income (profit) each year or ($2.68) on an earnings per share basis.

How many employees does Editas Medicine have?

Editas Medicine employs 208 workers across the globe.

What is Editas Medicine's official website?

The official website for Editas Medicine is www.editasmedicine.com.

Where are Editas Medicine's headquarters?

Editas Medicine is headquartered at 11 Hurley Street, Cambridge MA, 02141.

How can I contact Editas Medicine?

Editas Medicine's mailing address is 11 Hurley Street, Cambridge MA, 02141. The company can be reached via phone at 617-401-9000 or via email at [email protected]


This page was last updated on 3/3/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.